What Is Neulastim Filpeg Ziextendo (Pegfilgrastim)? How Is It Used, and What Are Its Side Effects?
In this article
Pegfilgrastimis the PEGylated, long-acting form of granulocyte colony-stimulating factor (G-CSF). In patients receiving myelosuppressive chemotherapy for nonmyeloid malignancies, it aims to reduce febrile neutropenia (FN) and related hospitalization/IV antibiotics requirements. G-CSF receptor activation stimulates proliferation/differentiation of granulocyte precursors, accelerates mature neutrophil release, and supports their function. A single 6 mg s.c. dose is given each cycle ≥24 hours after chemotherapy ; it is not given on the same day as chemotherapy or within 14 days before the next cycle.
Contents
- What is pegfilgrastim?
- Indication
- Mechanism of action
- Dose, timing, and administration
- Patient selection (primary/secondary prophylaxis)
- Contraindications & warnings
- Side effects
- Dose modification & monitoring algorithms
- Drug interactions
- Special situations
- Storage & logistics
- Home administration: step by step Patient guide
- SGK reimbursement (Türkiye)
- Frequently asked questions
- References
1) What Is Neulastim/Filpeg/Zıextendo?
Pegfilgrastim is available as a long-acting G-CSF preparation. By reducing the depth and duration of chemotherapy-induced neutropenia, it lowers FN risk. The prefilled syringe allows convenient single-dose administration each cycle.
2) Indication
- Oncology indication: In adult/pediatric patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy , reduced infection incidence (represented by FN) through prophylaxis.
- FDA/EMA: The reference pegfilgrastim product was first approved in 2002 (Neulasta®). Biosimilars and national brands carry the same class warnings.
- Position in guidelines (summary): For regimens with FN risk ≥20% , primary prophylaxis; at 10–20%, it may be considered with additional risk factors such as older age, comorbidities, previous FN, intensive combinations, or poor performance. For those with FN/dose delays in a previous cycle, secondary prophylaxis.
3) Mechanism of Action
Pegfilgrastim binds the G-CSF receptor, increasing granulocyte precursor proliferation and differentiation and accelerating mature neutrophil release from bone marrow. The PEG chain reduces renal clearance and extends half-life; the drug is cleared through neutrophil-mediated clearance and is self-regulated .
4) Dose, Timing, and Administration
| Group | Dose | Timing | Note |
|---|---|---|---|
| Adults (≥45 kg) | 6 mg s.c. (entire prefilled syringe) | In each chemotherapy cycle, ≥24 hours afterward | With chemotherapy, not on the same day; not within 14 days before the next cycle |
| Pediatric (<45 kg) | Weight-based (according to the product label table) | Each cycle | Volume adjustment and device selection must be performed by trained staff |
- Same-day rule: Do not give on the same day because of potential pharmacodynamic overlap with cytotoxic agents.
- Injection sites: Abdomen (≥5 cm from the navel), front-outer thigh, back-outer upper arm (with a caregiver).
- Analgesia: Paracetamol/NSAIDs may be chosen for bone pain if not contraindicated.
5) Patient Selection (Primary/Secondary Prophylaxis)
- Primary:
Pegfilgrastim may be used for primary prophylaxis with chemotherapy regimens carrying febrile neutropenia risk ≥20%, or for secondary prophylaxis in patients who developed febrile neutropenia or severe neutropenia in a previous cycle. (The indications of pegfilgrastim products may vary by brand.)
- Secondary: After FN, prolonged/grade 4 neutropenia, or a cycle delay in the previous cycle.
6) Contraindications & Critical Warnings
| Topic | Details |
|---|---|
| Contraindication | History of hypersensitivity to pegfilgrastim/filgrastim or excipients. After a serious reaction, do not readminister. |
| Splenic rupture | LUQ/shoulder pain, hypotension; emergency assessment, imaging, and appropriate management. |
| Acute Respiratory Distress Syndrome (ARDS) | Dyspnea, hypoxemia, infiltrates; consider stopping the drug and supportive treatment. |
| Capillary Leak Syndrome | Acute edema, sudden weight gain, hypotension, hemoconcentration; intensive care may be required. |
| Glomerulonephritis | Hematuria/proteinuria, increased creatinine; nephrology consultation, longer dosing intervals, or discontinuation. |
| Aortitis | Fever, back/abdominal pain, inflammatory markers; confirm with imaging and treat appropriately. |
| Sickle Cell Disease (SCD) | Risk of crisis; careful indication, education, and close monitoring. |
| Leukocytosis | Usually well tolerated clinically; monitor abnormal findings with complete blood counts. |
7) Side Effects
| Category | Example Findings | Management |
|---|---|---|
| Very common/Common | Bone/limb/back pain, headache, injection-site reaction | Stepwise analgesia (paracetamol/NSAIDs), local care; review regimen/analgesia for severe pain |
| Immune | Allergic reactions, rash/urticaria, anaphylaxis (rare) | Antihistamine for mild reactions; emergency management, epinephrine, and permanent discontinuation |
| Hematologic | Leukocytosis, thrombocytopenia (uncommon) | Monitor complete blood count in clinical context; assess if symptomatic |
| Respiratory | ARDS (rare but serious) | Emergency assessment, oxygenation, imaging; consider stopping the drug |
| Renal | Glomerulonephritis (hematuria/proteinuria), increased creatinine | Nephrology consultation; extend dosing intervals or discontinue |
| Vascular | Capillary leak, aortitis | Intensive support, inflammation control; treat underlying causes |
| Splenic | Enlargement/rupture | Image LUQ pain; emergency surgical assessment for rupture |
Warning symptoms: Fever of 38.0°C or above, sudden shortness of breath, generalized edema/hypotension, left upper quadrant pain, widespread rash/urticaria, and wheezing → seek emergency care.
8) Dose Modification & Monitoring
- Standard oncology prophylaxis: Routine adult dose reduction: none; a single 6 mg dose each cycle.
- Serious adverse event: For anaphylaxis, ARDS, capillary leak, splenic rupture, significant kidney injury, etc., stop the drug and manage with the appropriate specialties.
- Suggested monitoring: According to clinical context, complete blood count (particularly in initial cycles), urinalysis/renal function, and imaging for respiratory symptoms.
- Renal/hepatic impairment/older age: No specific PK-based dose adjustment is needed; clinical monitoring is essential.
9) Drug Interactions
- Timing with chemotherapy: Do not administer on the same day. Give at least 24 hours afterward .
- Hematologic influences: Lithium and other drugs increasing leukocytosis may theoretically enhance it; clinical monitoring is recommended.
- Vaccines: Live vaccines are generally deferred during chemotherapy; individualize planning.
- Other PK interactions: No clinically significant pharmacokinetic interaction is expected.
10) Special Situations
| Situation | Recommendation |
|---|---|
| Pregnancy/Lactation | Limited human data; individualize risk–benefit and seek specialist advice. |
| Pediatrics (<45 kg) | Weight-based dosing is mandatory; do not give a partial dose using an adult prefilled syringe. |
| Sickle Cell Disease | Risk of crisis; use only with a strong indication and close monitoring. |
| Nuclear Medicine Imaging | Increased bone marrow activity may cause false positives; note this in the report. |
11) Storage & Logistics
- 2–8 °C (refrigerated), protected from light and impact; keep in original packaging.
-
ZIEXTENZO may be exposed to room temperature (not exceeding 35°C) for up to 120 hours. Discard ZIEXTENZO® left at room temperature for more than 120 hours. FILPEG may be left at room temperature (not exceeding 25°C ± 2°C) for up to 72 hours on a single occasion. Discard FILPEG if left at room temperature for more than 72 hours.
-
Before administration, leave for ~30 minutes at room temperature ; do not shake, do not heat.
- At room temperature, do not exceed 48 hours in total. Prevent freezing; if frozen more than once, do not use.
- Maintain the cold chain and batch/lot records in home/clinic logistics.
12) Home Administration
- Confirm timing: After chemotherapy, ≥24 hours later; not within 14 days before the next cycle.
- Prepare: Prefilled syringe, alcohol wipe, cotton/gauze, adhesive dressing, sharps container.
- Warming: Remove from the refrigerator and leave at room temperature for ~30 minutes; do not shake, do not heat.
- Check: The solution should be clear and particle-free; check the expiry date and syringe integrity.
- Hygiene: Wash and dry your hands; clean the site with alcohol and let it dry.
- Choose the site: Abdomen (≥5 cm from the navel), thigh; each time, rotate the site.
- Technique: Gently pinch the skin; insert at 90° (45° if very thin); push the plunger slowly and steadily to deliver the full dose (10–30 seconds).
- Withdrawal: Remove at the same angle; press with cotton, do not rub. If there is an automatic needle guard, ensure it is fully activated.
- Disposal: Discard the syringe in a sharps container ; do not put it in household trash.
- Record: Note the date/time, injection site, and lot/batch number.
- Warning signs: 38.0°C+, shortness of breath, generalized edema/hypotension, left upper quadrant pain, widespread rash/urticaria → emergency care.
- If you miss a dose: Do not make up the dose yourself; arrange a new time with your team.
Use this guide only when your physician considers home administration appropriate and you have received individual training. Product label instructions take precedence.
13) SGK Reimbursement
- Coverage: Suitable for primary prophylaxis after chemotherapy regimens carrying febrile neutropenia risk ≥20% in patients receiving cytotoxic chemotherapy for malignancy (excluding chronic myeloid leukemia and myelodysplastic syndrome), or after cycles shown to cause febrile neutropenia or severe neutropenia (absolute neutrophil count <500 μl) for secondary prophylaxis. Filgrastim/lenograstim/pegfilgrastim/lipegfilgrastim products are reimbursed for cancer diagnoses. (Ziextendo: Suitable after cycles shown to cause febrile neutropenia or severe neutropenia (absolute neutrophil count <500 μl) in patients receiving cytotoxic chemotherapy for malignancy (excluding chronic myeloid leukemia and myelodysplastic syndrome).)
- Report: A 6-month maximum-duration medical board report; the board includes a hematology or medical oncology specialist.
- Prescribing: No more than one month's doses may be prescribed; consistency with the clinical indication and cycle intervals is required.
- Available in Türkiye under the names Neulastim, Filpeg, and Ziextendo.
- Price: Neulastim: 16.670.61TL, Ziextendo: 13.562.54 TL and Filpeg:12.794.86TL.
14) Frequently Asked Questions
Who is it preferred for? Anyone with a regimen FN risk ≥20%; at 10–20%, when additional risks are present. Secondary prophylaxis after FN/dose delays in a previous cycle.
Can it be given on the same day as chemotherapy? No. Give at least 24 hours afterward. The next dose can be given at least 14 days later.
What if bone pain is severe? Paracetamol/NSAIDs (if appropriate), local measures; report persistent pain to your team.
15) References
- Neulasta® (pegfilgrastim) Prescribing Information — dose, timing, warnings.
- EMA SmPC — pegfilgrastim and biosimilars: indication, storage, safety.
- NCCN Guidelines®: Hematopoietic Growth Factors — primary/secondary prophylaxis criteria.
- ASCO CSF Kılavuzu — patient- and regimen-based decision principles for FN prophylaxis.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.